EuroBiotech: More Articles of Note


> Enterome teamed up with Memorial Sloan Kettering Cancer Center to assess the use of gut microbiome-derived antigens in cancer. Release 

> 4D pharma presented early data from a trial testing bacterium MRx0518 in combination with Merck’s Keytruda. Two of the first six patients had a “clinically relevant response.” Statement 

> Artios Pharma in-licensed a small-molecule ATR inhibitor developed by MD Anderson Cancer Center and ShangPharma. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Vaccibody presented early data from a phase 1/2a trial of neoantigen cancer vaccine VB10.NEO. Clinical responses were seen in half of the first 14 patients. Statement

> Oxford Drug Design secured £2.2 million ($2.8 million) to fund work to tackle antimicrobial resistance. Release 

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.